NA Semax Amidate

NA Semax Amidate is a structure-optimized analog of semax. It is an N-terminally acetylated and C-terminally amidated derivative of the Semax peptide, which preserves the core sequence.

 

SKU: 198886 קאַטעגאָריע:
ייַנטיילן דיין ליבע

NA Semax Amidate is a structure-optimized analog of semax. It is an N-terminally acetylated and C-terminally amidated derivative of the Semax peptide, which preserves the core sequence.

This artificial modification markedly improves the resistance of the peptide chain against exo- and endopeptidases (for example leucine aminopeptidase), extending its half-life by about 30 minutes compared with the original Semax, with an overall duration of action of 6-12 שעה.

It also enhances room temperature storage stability and nasal mucosal absorption efficiency, thereby ensuring more reliable penetration of the blood-brain barrier (BBB) and the sustained maintenance of an effective concentration gradient in brain tissue.

Its core mechanism lies in multi-pathway modulation of central nervous system פֿונקציע.

First and foremost, NA Semax Amidate acts as a powerful upregulator of מאַרך-דערייווד נעוראָטראָפיק פאַקטאָר (BDNF), which in turn enhances neuronal survival, axonal growth, סינאַפּטיק פּלאַסטיסיטי און long-term potentiation (LTP) — the molecular basis for learning and memory.

דערצו,NA Semax Amidate potentiates dopaminergic, serotonergic, and noradrenergic neurotransmission, thereby optimizing prefrontal cortex executive functions, including attention selectivity and working memory capacity.

NA Semax Amidate also exhibits significant neuroprotective effects by suppressing inflammatory cytokine release, reducing oxidative stress damage, and stabilizing mitochondrial membrane potential.

It is effective against various pathological insults such as cerebral ischemia, היפּאָקסיאַ, trauma, און neurodegeneration.

It is approved in Russia as adjunctive therapy for acute stroke, traumatic brain injury, and early-stage Parkinson’s disease.

In summary, NA Semax Amidate utilizes chemical modifications to overcome the limitations of the natural peptide, thereby surpassing conventional Semax in cognitive enhancement, neuroprotection, mood regulation, and injury repair.

This holds significant clinical importance for the treatment of נעוראָדעגענעראַטיווע חולאתן and the promotion of central nervous system functional recovery.

סיקוואַנס

AC-met-glu-his-phe-pro-gly-pro-nh2

CAS נומער

/

מאָלעקולאַר פאָרמולע

C39H54N10O10S

מאָלעקולאַר וואָג

854.98

Research Of NA Semax Amidate

NA Semax Amidate demonstrates efficacy comparable to classical anxiolytic drugs in several preclinical models.

1.Cognitive Enhancement and Neural Plasticity

NA Semax Amidate activates the transcription factor CREB, upregulating BDNF gene expression and increasing neuronal BDNF levels by over 40%.

This in turn promotes dendritic spine פאָרמירונג, axonal guidance, and aggregation of postsynaptic density protein 95 (PSD-95), thereby enhancing learning capacity.

Biological simulation experiments demonstrate a 35-50% improvement in memory retention rates in contextual fear conditioning tests.

Brain slice electrophysiological recordings confirm increased LTP amplitude and duration, indicating that NA Semax Amidate reshapes סינאַפּטיק פּלאַסטיסיטי thresholds through profound activation of the נעוראָטראָפיק פאַקטאָר network.

2.Neuroprotection and Repair

NA Semax Amidate activates the adenylate cyclase (AC)-cAMP-PKA pathway to stabilize מיטאָטשאָנדריאַל membrane potential, inhibits cytochrome C release, and suppresses caspase-3 cascade activation, thereby blocking the execution phase of אַפּאָפּטאָסיס.

Concurrently, it upregulates סופּעראָקסידע דיסמוטאַסע expression and inhibits excessive inflammatory סיטאָקינע פּראָדוקציע.

In a rat middle cerebral artery occlusion model, it reduced cerebral infarction volume by over 50%.

In an MPTP model of Parkinson’s disease, it increased dopaminergic neuron survival by 35%, demonstrating potent neuroprotection.

3.Anxiolytic and Analgesic Effects

NA Semax Amidate increases affinity for endogenous enkephalins און β-endorphin while inhibiting G protein-coupled receptor kinase (GRK)-mediated receptor internalization and desensitization, thereby prolonging analgesic signaling.

It also reduces FTO-mediated inflammatory pain hypersensitivity.

In mouse models, pain thresholds were elevated by 30-40% and remained elevated for 4 צו 6 שעה.

In chronic constriction injury (CCI) models, mechanical allodynia was alleviated by 50%, further confirming NA Semax Amidate’s clear anti-stress and mood-stabilizing properties.

NA Semax Amidate demonstrates efficacy comparable to classical anxiolytic drugs in several preclinical models.

4.Cognitive Enhancement and Neural Plasticity

NA Semax Amidate activates the transcription factor CREB, upregulating BDNF gene expression and increasing neuronal BDNF levels by over 40%.

This in turn promotes dendritic spine formation, axonal guidance, and aggregation of postsynaptic density protein 95 (PSD-95), thereby enhancing learning capacity.

Biological simulation experiments demonstrate a 35-50% improvement in memory retention rates in contextual fear conditioning tests.

Brain slice electrophysiological recordings confirm increased LTP amplitude and duration, indicating that NA Semax Amidate reshapes synaptic plasticity thresholds through profound activation of the neurotrophic factor network.

5.Neuroprotection and Repair

NA Semax Amidate activates the adenylate cyclase (AC)-cAMP-PKA pathway to stabilize mitochondrial membrane potential, inhibits cytochrome C release, and suppresses caspase-3 cascade activation, thereby blocking the execution phase of apoptosis.

Concurrently, it upregulates superoxide dismutase expression and inhibits excessive inflammatory cytokine production.

In a rat middle cerebral artery occlusion model, it reduced cerebral infarction volume by over 50%.

In an MPTP model of Parkinson’s disease, it increased dopaminergic neuron survival by 35%, demonstrating potent neuroprotection.

6.Anxiolytic and Analgesic Effects

NA Semax Amidate increases affinity for endogenous enkephalins and β-endorphin while inhibiting G protein-coupled receptor kinase (GRK)-mediated receptor internalization and desensitization, thereby prolonging analgesic signaling.

It also reduces FTO-mediated inflammatory pain hypersensitivity.

In mouse models, pain thresholds were elevated by 30-40% and remained elevated for 4 צו 6 שעה.

In chronic constriction injury (CCI) models, mechanical allodynia was alleviated by 50%, further confirming NA Semax Amidate’s clear anti-stress and mood-stabilizing properties.

COA

HPLC

MS

(1) דמיטריעוואַ, V. ג.; פּאָוואַראָוואַ, אָ. V.; סקוואָרצאָוואַ, V. איך.; לימבאָרסקאַ, ש. א.; מיאַסאָעדאָוו, נ. פ.; דערגונאָוואַ, ל. V. Semax און Pro-Gly-Pro אַקטאַווייט די טראַנסקריפּציע פון ​​נעוראָטראָפינס און זייער רעסעפּטאָר גענעס נאָך סערעבראַל יסטשעמיאַ. סעליאַלער און מאָלעקולאַר נעוראָביאָלאָגי 2009, 30 (1), 71-79. DOI: 10.1007/s10571-009-9432-0.

(2) ערעמין, ק. אָ.; קודרין, V. ש.; סאַראַנסאַרי, פּ.; פּראָדוקט, ש. ש.; גריווענניקאָוו, איך. א.; מיאַסאָעדאָוו, נ. פ.; ראיעװסקי, ק. ש. דו זאלסט נישט הערן, אַן ACTH(4-10) אַנאַלאָג מיט נאָאָטראָפּיק פּראָפּערטיעס, אַקטאַווייץ דאָפּאַמינערגיק און סעראַטאָונינערגיק מאַרך סיסטעמען אין ראָודאַנץ. נעוראָטשעמיקאַל פאָרשונג 2005, 30 (12), 1493-1500. DOI: 10.1007/s11064-005-8826-8.

(3) גלאַזאָוואַ, נ. י.; מאַנטשענקאָ, ד. מ.; וואָלאָדינאַ, מ. א.; מערטשיעוואַ, ש. א.; אַנדרעעוואַ, ל. א.; קודרין, V. ש.; מיאַסאָעדאָוו, נ. פ.; לעוויצקאיא, נ. ג. דו זאלסט נישט הערן, סינטעטיש ACTH(4–10) אַנאַלאָג, אַטטענואַטעס נאַטוראַל און נעוראָטשעמיקאַל אָלטעריישאַנז נאָך ויסשטעלן פון פלווואָקסאַמינע אין פרי-לעבן אין ווייַס ראַץ. נעוראָפּעפּטידעס 2021, 86. DOI: 10.1016/דזש.נפּעפּ.2020.102114.

(4) קאָסטן, נ. V.; סאָקאָלאָוו, אָ.; Gabaeva, מ. V.; גריווענניקאָוו, איך. א.; אַנדרעעוואַ, ל. א.; מיאַסאָעדאָוו, נ. פ.; זוזוליאַ, א. א. [סעמאַקס און סעלאַנק ינכיבאַט די ענקעפאַלין-דיגריידינג ענזימעס פון מענטש סערום]]. ביאורג כים 2001, 27 (3), 180-183. DOI: 10.1023/א:1011373002885 פֿון NLM Medline.

(5) מעדוועדעוואַ, E. V.; דמיטריעוואַ, V. ג.; לימבאָרסקאַ, ש. א.; מיאַסאָעדאָוו, נ. פ.; דערגונאָוואַ, ל. V. דו זאלסט נישט הערן, אַן אַנאַלאָג פון ACTH(4−7), רעגיאַלייץ אויסדרוק פון ימיון ענטפער גענעס בעשאַס יסטשעמיק מאַרך שאָדן אין ראַץ. מאָלעקולאַר גענעטיק און גענאָמיקס 2017, 292 (3), 635-653. DOI: 10.1007/s00438-017-1297-1.

(6) פּאַע, C.-U. טעראַפּיוטיק מעגלעכקייט פון "סעמאַקס" פֿאַר דעפּרעסיע. CNS ספּעקטרום 2014, 13 (1), 20-21. DOI: 10.1017/s1092852900016102.

(7) וולאַסאָוואַ, איך. מ.; בוראװטקאװ, ד. E.; סאלעצקי, א. מ. לומינעססענסע אַנאַליסיס פון בלוט קאַמפּאָונאַנץ אין שטודיום פון נעוראָפּראָטעקטיוו פּראָפּערטיעס פון די מעדיצין "Semax" אין סערעבראַל יסטשעמיאַ. זשורנאַל פון אַפּפּליעד ספּעקטראָסקאָפּי 2009, 76 (1), 121-126. DOI: 10.1007/s10812-009-9141-י.

סיקוואַנס:

AC-met-glu-his-phe-pro-gly-pro-nh2

CAS:

/

מ.וו:

854.98 ג / מאָל

היים זוכן ווהאַצאַפּפּ סערוויסעס פּראָדוקט